Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma

Trial ID or NCT#

NCT00352027

Status

not recruiting iconNOT RECRUITING

Purpose

The main purpose of this protocol is to estimate the percentage of patients with intermediate risk Hodgkin lymphoma who will survive free of disease (Event-free survival) for three years after treatment with multi-agent chemotherapy (Stanford V) and low-dose, tailored-field radiation therapy. The hypothesis being studied is that this treatment will result in more than 80% of patients being alive and free of disease three years after starting treatment.

Official Title

Stanford V Chemotherapy With Low-Dose Tailored-Field Radiation Therapy for Intermediate Risk Pediatric Hodgkin Lymphoma

Eligibility Criteria

Ages Eligible for Study: Younger than 21 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Patient is less than or equal to 21 years of age - Patient has a confirmed diagnosis of previously untreated Hodgkin lymphoma - Has Ann Arbor stage IB, IIIA, or IA/IIA with extranodal extension, multiple nodal involvement (3 or more sites), or bulky mediastinal adenopathy.
Exclusion Criteria:
  1. - Patients with favorable risk features - Patients with unfavorable risk features - Patients who have received prior therapy for Hodgkin lymphoma.

Investigator(s)

Michael Link

Contact us to find out if this trial is right for you.

Contact

Peds Hem/Onc CRAs
650-723-5535